Colchicine

Introduction Overview

Generic Name

colchicine

Brand Name

Colcrys, Gloperba, Mitigare, Lodoco

Dosage Form

oral tablet, oral capsule, oral solution

Drug Class

Antigout agents

Pharmacokinetics

Absorption: Colchicine is rapidly and efficiently absorbed when administered orally, across the gastrointestinal tract including the stomach and small intestine. The oral bioavailability of colchicine varies due to first-pass metabolism and interindividual variability but is generally within the range of 40-50%. Food does not significantly affect colchicine absorption and thus the drug can be administered with or without food. The peak plasma concentration is typically attained within 1 to 2 hours post-dose, enabling rapid onset of action in acute inflammatory episodes such as gout flares.

Distribution: Colchicine exhibits a large volume of distribution, estimated at approximately 5 to 8 L/kg, indicating extensive tissue penetration. It preferentially accumulates in leukocytes, kidney, liver, spleen, and gastrointestinal tract tissues, which is consistent with its therapeutic and toxicological profiles. Binding to plasma proteins is approximately 40%, primarily to albumin. The intracellular concentration within neutrophils is critical for its anti-inflammatory effects, as colchicine disrupts microtubule formation in these cells.

Metabolism: Colchicine undergoes extensive hepatic metabolism primarily via demethylation mediated by cytochrome P450 CYP3A4 enzymes. The fast hepatic metabolism reduces systemic exposure but also leads to a significant potential for drug-drug interactions with strong CYP3A4 inhibitors, which can increase colchicine plasma levels and toxicity risk. Additionally, colchicine is a substrate of P-glycoprotein (P-gp), influencing its bioavailability and excretion.

Elimination: The elimination half-life of colchicine ranges between 20 to 40 hours, with renal and biliary routes contributing to elimination. Approximately 10-20% of colchicine is excreted unchanged in the urine. Impaired renal or hepatic function can significantly prolong colchicine clearance and increase systemic exposure, necessitating dose adjustment and heightened monitoring to avoid toxicity. Enterohepatic recirculation contributes to its prolonged action. Given colchicine's narrow therapeutic index, elimination kinetics are critical for safe dosing.

Dosage Forms

Available Dosage Forms: Colchicine is available in multiple oral formulations to accommodate different patient age groups and clinical indications. These include:
- Oral tablets: Colcrys tablets contain colchicine 0.6 mg active ingredient.
- Oral capsules: Mitigare capsules containing colchicine 0.6 mg.
- Oral solution: Gloperba oral solution, with dosage strength of 0.6 mg colchicine per 5 mL.
- Lodoco tablets with colchicine 0.5 mg, used uniquely for cardiovascular risk reduction.

Dosages for Adults and Adolescents:
- For gout flare treatment (Colcrys tablets): Initial dose of 1.2 mg (two 0.6 mg tablets) at first sign of flare, followed by 0.6 mg one hour later, maximum 1.8 mg over one hour; dosing should not be repeated within 3 days.
- For prevention of gout flares: 0.6 mg once or twice daily (maximum 1.2 mg/day) using Colcrys tablets, Mitigare capsules, or Gloperba solution.
- Familial Mediterranean Fever (FMF): Colcrys tablets 1.2 to 2.4 mg daily for adults and children older than 12 years, divided into one or two doses; lower doses are recommended for younger children (children 6-12 years: 0.9-1.8 mg; 4-6 years: 0.3-1.8 mg).
- For Behçet disease: Generic colchicine used in experimental doses ranging from 0.6 mg to 2 mg daily in divided doses.
- Cardiovascular risk reduction (Lodoco tablets): 0.5 mg once daily.

Specific Patient Populations: Dose adjustments are essential in patients with renal or hepatic impairment to mitigate accumulation and adverse effects. Pediatric dosing varies depending on age and indication, particularly for FMF management. Older adults should be monitored closely due to altered pharmacokinetics and increased susceptibility to toxicity. Use during pregnancy and breastfeeding requires risk-benefit assessment. Administration to patients taking interacting medications such as CYP3A4 or P-gp inhibitors warrants significant dose reduction or avoidance.

Mechanism Of Action

Colchicine primarily exerts its therapeutic effects through disruption of the cytoskeletal microtubules within inflammatory cells. It binds to tubulin subunits, preventing their polymerization to microtubules, which plays a critical role in cellular functions such as migration, division, and intracellular trafficking. This inhibition impairs neutrophil motility and degranulation, reducing their migration to sites of inflammation and the resultant inflammatory cascade.

At the molecular level, colchicine inhibits the assembly of the inflammasome complex in neutrophils and monocytes, leading to decreased activation of caspase-1 and subsequent reduction in the production of interleukin-1β (IL-1β), a potent pro-inflammatory cytokine. This mechanism is central in mitigating the acute inflammatory response induced by monosodium urate crystals in gout.

Clinically, colchicine’s anti-inflammatory properties do not directly lower uric acid levels but effectively diminish the inflammatory symptoms of gout flares, Familial Mediterranean fever, and Behçet disease by modulating the innate immune response. Recent evidence also suggests potential benefits in cardiovascular diseases by reducing systemic inflammation and preventing neutrophil-platelet interactions implicated in atherothrombosis.

Compared with other antigout agents like NSAIDs or corticosteroids, colchicine offers a unique mechanism by specifically targeting microtubule dynamics in white blood cells, providing an alternative anti-inflammatory pathway. This distinct mode of action undergirds its use in patients intolerant to or contraindicated for other anti-inflammatory drugs. Extensive clinical studies confirm colchicine’s efficacy and tolerability at approved dosages, extending its utility beyond rheumatologic diseases into cardiovascular risk mitigation.

Pharmacological Actions

Inhibits microtubule polymerization by binding to tubulin, disrupting cytoskeletal functions
Suppresses neutrophil chemotaxis and adhesion, reducing migration to inflammatory sites
Inhibits activation of the NLRP3 inflammasome and subsequent IL-1β production
Modulates inflammatory pathways without affecting uric acid synthesis or excretion
Reduces phagocytosis and release of pro-inflammatory mediators from leukocytes
Attenuates the inflammatory response in gout flares, Familial Mediterranean fever, and Behçet disease
Decreases platelet aggregation and inflammatory cell interaction, potentially reducing cardiovascular events
Exerts immunomodulatory effects by impairing mitosis in rapidly dividing cells
Displays antiproliferative effects in some models due to impaired tubulin function
Blocks microtubule-dependent processes critical for cell motility and secretory functions

Therapeutic Or Clinical Uses

Treatment and prevention of acute gout flares in adults
Prevention of recurrent gout attacks in adults and adolescents 16 years and older
Management of Familial Mediterranean fever (FMF) in adults and children aged 4 years and older
Treatment of inflammatory symptoms associated with Behçet disease such as pain, swelling, and redness
Reduction of risk of heart attack, stroke, and cardiovascular death in adults with high cardiovascular risk
Adjunct therapy in diseases requiring modulation of neutrophil-mediated inflammation
Experimental or off-label use in other autoinflammatory syndromes
Used in patients intolerant or contraindicated for NSAIDs or corticosteroids for gout
Supportive treatment in amyloidosis related to FMF
Investigational uses in viral infections and COVID-19 due to anti-inflammatory properties

Side Or Adverse Effects

Common gastrointestinal symptoms: diarrhea, nausea, vomiting, abdominal pain
Myelosuppression including leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia
Muscle weakness or myopathy, sometimes associated with neuropathy (numbness or tingling in extremities)
Potential for severe toxicity and fatality with overdose due to narrow therapeutic index
Rare infertility or transient impairment of male fertility
Rare hypersensitivity reactions including rash and urticaria
Hepatotoxicity with elevated liver enzymes in rare cases
Neuromuscular toxicity, particularly in patients with renal impairment or concomitant statin use
Severe diarrhea as an early indicator of colchicine toxicity
Increased susceptibility to infections due to immune suppression
Risk of blood dyscrasias necessitating routine blood count monitoring
Potential teratogenicity and risk during pregnancy
Elevated risk of adverse reactions when combined with CYP3A4 or P-glycoprotein inhibitors
Possible renal and hepatic adverse events in patients with organ dysfunction

Precautions

Use with caution in patients with renal or hepatic impairment due to increased toxicity risk
Adjust dosing or avoid use in patients taking strong CYP3A4 or P-glycoprotein inhibitors
Monitor complete blood counts regularly due to risk of bone marrow suppression
Avoid use in patients with pre-existing blood dyscrasias or bone marrow suppression
Do not exceed recommended doses given narrow therapeutic window and high overdose risk
Avoid grapefruit and grapefruit juice consumption during treatment to prevent drug interactions
Evaluate pregnancy status; weigh benefits versus risks as safety in pregnancy is uncertain
Breastfeeding decisions should consider potential for exposure and infant monitoring
Instruct patients to recognize early signs of toxicity such as severe diarrhea or muscle weakness
Children require careful dosing and monitoring due to higher sensitivity and toxicity risk
Discontinue and seek medical attention immediately if severe adverse effects occur
Use caution when co-administering with statins or fibrates due to potential for myopathy
Avoid abrupt discontinuation without healthcare provider guidance to prevent disease exacerbation
Be aware of potential for transient fertility impairment in males during treatment

Warnings

Fatal overdose risk due to narrow margin between therapeutic and toxic doses
Serious adverse effects including bone marrow suppression and muscle toxicity reported
Contraindicated in patients with severe renal or hepatic impairment using interacting drugs
Life-threatening interactions can occur with concurrent use of CYP3A4 and P-gp inhibitors
Gastrointestinal symptoms such as severe diarrhea can signal impending toxicity
Potential for cumulative toxicity leading to multi-organ failure if improperly dosed
Increased risk of muscle toxicity when combined with statins, fibrates, or cyclosporine
Pregnancy and breastfeeding require careful risk assessment due to limited safety data
Avoid use in patients with pre-existing blood disorders due to bleeding risk
Patients must be educated on the critical importance of adherence to dosing schedules
Use with caution in elderly due to altered pharmacokinetics and comorbidities
Risk of infections due to immunosuppressive actions necessitates infection monitoring
Do not start new therapies without consulting healthcare provider due to interaction risks
Store securely to prevent accidental ingestion, which can be fatal especially in children

Contraindication

Hypersensitivity or allergy to colchicine or any formulation components
Severe renal or hepatic impairment when used concomitantly with certain interacting drugs
Patients with pre-existing blood dyscrasias including leukopenia, thrombocytopenia, aplastic anemia
Concomitant use with strong CYP3A4 inhibitors and P-glycoprotein inhibitors without dose adjustment
Known history of colchicine toxicity or overdose
Concurrent use with medications that significantly increase colchicine plasma levels without supervision
Pediatric patients under 4 years for Familial Mediterranean fever without specialist guidance
Co-administration with drugs causing additive bone marrow suppression or myopathy
Pregnancy where potential benefits do not outweigh risks, unless prescribed by expert
Patients with severe gastrointestinal disease where absorption may lead to toxicity

Drug Interactions

CYP3A4 inhibitors such as clarithromycin, ketoconazole, itraconazole significantly increase colchicine levels
P-glycoprotein inhibitors like cyclosporine, verapamil increase colchicine toxicity risk
HMG CoA reductase inhibitors (statins) combined with colchicine potentiate muscle toxicity and rhabdomyolysis
Fibrates (gemfibrozil, fenofibric acid) increase risk of muscle-related adverse effects
Macrolide antibiotics (e.g., clarithromycin) strongly interact, raising plasma colchicine concentrations
Antiviral protease inhibitors (atazanavir, lopinavir/ritonavir, darunavir, nelfinavir) potentiate colchicine toxicity
Telithromycin and other ketolide antibiotics increase colchicine exposure and side effects
Certain antidepressants (nefazodone) may amplify toxicity due to CYP3A4 inhibition
Digoxin co-administration may require monitoring for additive toxicities
Grapefruit juice inhibits CYP3A4 leading to increased colchicine blood levels
Co-administration with other myelosuppressive agents increases risk of severe blood dyscrasias
Drugs affecting renal or hepatic clearance may alter colchicine pharmacokinetics
Short courses of antibiotics can cause dangerous interactions if combined with colchicine
Concurrent use with inducers of CYP3A4 (like rifampin) may reduce colchicine effectiveness

Preparations Of The Drug

Colcrys 0.6 mg tablets: Includes inactive ingredients such as carnauba wax, FD&C blue #2 and red #40, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, titanium dioxide, triacetin
Mitigare 0.6 mg capsules: Contains inactive ingredients including colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose, sodium starch glycolate; capsule shell composed of gelatin, purified water, titanium dioxide, erythrosine, Brilliant Blue FCF, Quinoline Yellow
Lodoco 0.5 mg tablets: Contains gelatin, lactose monohydrate, magnesium stearate, potato starch, and talc as inactive ingredients
Gloperba 0.6 mg/5 mL oral solution: Formulated with benzyl alcohol, FD&C Red No. 40, artificial cherry flavor, anhydrous citric acid, dibasic sodium phosphate, glycerin, propylene glycol, sucralose, xanthan gum, and purified water
Generic colchicine 0.6 mg tablets and capsules: Composition varies by manufacturer; refer to specific medication guide for excipients
All preparations are manufactured with high-quality standards to ensure consistent dosage and stability
Variety of manufacturers include Takeda Pharmaceuticals (Colcrys), West-Ward Columbus Inc. (Mitigare), Scilex Pharmaceuticals (Gloperba), Agepha Pharma (Lodoco), among others
Packaging includes child-resistant containers and should be stored at controlled room temperature between 20°C and 25°C
Formulations are designed for oral administration with easy dosing for acute and chronic therapy
Liquid formulation Gloperba offers dosing flexibility especially for patients with swallowing difficulties or pediatric use